866-997-4948(US-Canada Toll Free)

Eosinophilic Esophagitis - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Diseases & Conditions

No. of Pages : 59 Pages

Eosinophilic Esophagitis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2017, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 4 and 4 respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Eosinophilic Esophagitis - Overview
Eosinophilic Esophagitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Eosinophilic Esophagitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
Adare Pharmaceuticals Inc
Calypso Biotech SA
Celgene Corp
DBV Technologies SA
Dr. Falk Pharma GmbH
Quorum Innovations LLC
Regeneron Pharmaceuticals Inc
Shire Plc
Eosinophilic Esophagitis - Drug Profiles
Allergen for Milk Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPRX-060216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CALY-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qi-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPC-4046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Eosinophilic Esophagitis - Dormant Projects
Eosinophilic Esophagitis - Product Development Milestones
Featured News & Press Releases
Feb 03, 2017: DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis
Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses
Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy
Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions
Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis
Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin Milk in Milk-Induced Eosinophilic Esophagitis in Children
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients
Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis
May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children
Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis
May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis
May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Eosinophilic Esophagitis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals Inc, H1 2017
Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H1 2017
Eosinophilic Esophagitis - Pipeline by Celgene Corp, H1 2017
Eosinophilic Esophagitis - Pipeline by DBV Technologies SA, H1 2017
Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H1 2017
Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H1 2017
Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Eosinophilic Esophagitis - Pipeline by Shire Plc, H1 2017
Eosinophilic Esophagitis - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Eosinophilic Esophagitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *